PP_1170x120_10-25-21

November 22, 2021

You can read the full November 22 print issue of Chain Drug Review in its entirety here. In CDR’s digital editions, you can find special sections and additional pages not posted online. You will need to register, but subscription is free!

How iA’s therapy management solutions help patients

How iA’s therapy management solutions help patients

With our iA customers, we see how pharmacy providers are increasingly competing to offer the best experience to attract and retain patients and customers. An important aspect of this commitment is spending time with patients and giving patients the choice of when, where and how they receive their prescriptions. The introduction of therapy management solutions

BD probes effects of prefilled syringe cold storage

BD probes effects of prefilled syringe cold storage

Scientists researched, developed and tested COVID-19 vaccines in record time — then the race to manufacture and deliver them to health care sites around the world began. To save lives, the vaccination program was rapidly rolled out. On the front line, pharmacists, nurses and doctors worked day and night to vaccinate the most vulnerable patients

Biosimilars are key to competition

Biosimilars are key to competition

It has been a big fall for interchangeable biologics. President Biden’s Executive Order 14036, “Promoting Competition in the American Economy” directed the Department of Health and Human Services (and the Food and Drug Administration), and HHS subsequently published its “Comprehensive Plan for Addressing High Drug Prices.” Interchangeable biosimilars are front and center in both of

Retail should get behind vaccine mandate

Retail should get behind vaccine mandate

Like many other policies intended to curb the spread of COVID-19, the Biden administration’s emergency temporary standard (ETS), which requires companies with 100 or more employees to ensure that members of their workforce are immunized or undergo weekly testing, has become a flashpoint. In addition to expected resistance from many Republicans, some business groups, including